Influence of the Nonergot Dopamine Agonist Piribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PiViCog-PD)-Reference-Cited by-同舟云学术

Influence of the Nonergot Dopamine Agonist Piribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PiViCog-PD)

Published:2014-07 Issue:4 Volume:37 Page:116-122
ISSN:0362-5664
Container-title:Clinical Neuropharmacology
language:en
Short-container-title:

Author:

Eggert Karla,Öhlwein Christian,Kassubek Jan,Wolz Martin,Kupsch Andreas,Ceballos-Baumann Andres,Ehret Reinhard,Polzer Udo,Klostermann Fabian,Schwarz Johannes,Fuchs Gerd,Jost Wolfgang,Albert Anita,Haag Anja,Hermsen Anke,Lohmüller Karin,Kuhn Katrin,Wangemann Martina,Oertel Wolfgang H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Clinical Neurology,Pharmacology

Reference37 articles.

1. Predictors of nursing home placement in Parkinsons disease: a population-based study.;Aarsland;J Am Geriatr Soc,2000

2. Colosimo, et al. The Priamo study: multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinsons disease.;Barone;Mov Disord,2009

3. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinsons disease.;Paus;Mov Disord,2003

4. Non-motor aspects of Parkinsons diesease.;Borek;CNS Spectr,2006

5. Impaired attention predicts falling in Parkinsons disease.;Allcoock;Parkinsonism Relat Disord,2009

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dopamine agonists in the treatment of Parkinson's disease: the show must go on;Journal of Neural Transmission;2024-09-11

2. Daytime sleepiness in Parkinson's disease: a multifaceted symptom;Frontiers in Sleep;2023-12-22

3. Cognitive Impairment in Parkinson’s Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches;Medicina;2023-10-01

4. Parkinson’s disease. Focus on early stages;Neurology, Neuropsychiatry, Psychosomatics;2023-07-04

5. Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease;Current Neuropharmacology;2023-05